Page 1

ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email!

Global Markets and Technologies for Pandemic Control Published on March 2013

Report Summary REPORT SCOPE INTRODUCTION REASONS FOR DOING THE STUDY The spread of human immunodeficiency virus (HIV), hepatitis B and C, evolving influenza strains and antibiotic-resistant organisms have put healthcare agencies on guard to avert pending pandemics from these diseases. They have also alerted healthcare professionals to the possibility of the use of viruses and bacteria in bioterrorism threats. The problem of antimicrobial resistance poses a global threat to the effective treatment of many bacterial diseases. Additionally, the emergence of drug-resistant strains of HIV and hepatitis have jolted the healthcare community out of its relative complacency about the threat of infectious diseases and prompted diagnostic and pharmaceutical manufacturers to bolster their infectious disease pipelines. Multidrug-resistant tuberculosis is no longer confined to any one country or to those individuals who are co-infected with HIV. A number of multidrug resistant microbes such as methicillin-resistant Staphalococcus auerus (MRSA) and vancomycin-resistant Enterococcus (VRE) that were once found only in hospitals or nursing homes are now active in the community at large. The rate of HIV infection combined with resistance to existing HIV and acquired immunodeficiency syndrome (AIDS) drugs and the obstacles encountered in developing an AIDS vaccine have resulted in a full-blown pandemic. Further, drug resistance in the treatment of HIV/AIDS necessitates the use of complex dosage protocols with unpleasant side effects that often further debilitate patients. Solutions to the dilemma of drug resistance involve management approaches on a worldwide scale (such as the implementation of rigorous surveillance of resistant organisms), better education of healthcare workers about appropriate use of antibiotics and closer monitoring of antibiotics used in animal and plant crops. Combined with these organizational activities is the need for new and effective drugs. New drugs to treat bacterial diseases and HIV/AIDS are being developed, but a new class of drugs to treat bacterial infections has not been developed since 2003, underscoring the need for more development in this area. SCOPE OF REPORT This report provides an in-depth look at the emerging pandemic of antibiotic resistance and the established viral pandemic of HIV/AIDS. It also provides historical, epidemiological and market information on hepatitis B and C, tuberculosis and malaria. This report also investigates bacterial and viral diseases that are emerging as health threats because of inadequate or nonexistent preventive and/or therapeutic products to combat them. Antibiotic-resistant organisms wreak havoc with international healthcare systems as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE) and Clostridium difficile (C. diffile) become more pervasive. These infections represent future pandemics if no suitable antibiotics are developed to counteract them. At present, each is problematic, but remains at an epidemic level, primarily within healthcare institutions and nursing facilities. Consequently, these infections are covered descriptively within the report, but are not yet classified as pandemics, nor measured quantitatively as part of the overall market for pandemics. The report outlines the available preventative and diagnostic products used to combat current and future pandemic infections and

Global Markets and Technologies for Pandemic Control (From Issuu)

Page 1/22


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! projects markets for these products. Forecasts are provided for the diagnostic and pharmaceutical markets for products to treat HIV/AIDS, hepatitis B and C, malaria and tuberculosis. Forecasts and trends are gleaned from industry sources as well as from an assessment of emerging products and technologies. The causes, the extent of impact and strategies to monitor, treat and prevent resistant diseases are assessed. The mechanisms by which drugs function to combat resistant microbes are described. Drugs that show promise of long-term activity (i.e., low likelihood of resistance) and their effects on the market are assessed. METHODOLOGY/INFORMATION SOURCES The data for this report were gathered from primary and secondary sources, including information obtained from industry analysts, manufacturer and company reports, industry trade journals, medical journals and industry associations. Additional information was obtained through the U.S. Patent and Trademark Office (USPTO), U.S. Securities and Exchange Commission (SEC) filings, The World Health Organization (WHO), the Organisation for Economic Cooperation and Development (OECD), the Mayo Clinic, the Pharmaceutical Research and Manufacturing Association and the Joint United Nations Programme on HIV/AIDS (UNAIDS). Where precise information was not available, projections were made using reasonable assumptions and estimates based on historical data. Market data are based on manufacturers' sales. INTENDED AUDIENCE This updated version of the pandemic market and technologies will be a valuable tool for decision makers, marketing personnel and manufacturers in both the diagnostic and pharmaceutical treatment industries. Individuals at research foundations, manufacturing companies and university laboratories will find valuable information on the global diagnostic product and pharmaceutical industries. ANALYST CREDENTIALS Peggy S. Lehr is the BCC Research analyst of this report. Ms. Lehr holds a BS in Journalism from the University of Colorado, Boulder, and a MS in Communication from the University of Denver. Ms. Lehr has worked as a researcher, editor and publisher within the publishing industry for both for-profit and not-for-profit organizations. REPORT HIGHLIGHTS The report provides: ' An overview of the products in development to treat bacterial diseases, especially those caused by drug-resistant organisms, and HIV/AIDS ' Analyses of market trends, with data from 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017 ' Clarification of the HIV/AIDS pandemic and ongoing efforts to control it ' Discussion of emerging threats, such as multidrug-resistant tuberculosis, West Nile virus and other serious viral diseases ' Trends based on projected sales through 2017 for new products, including supporting analyses for projections. ' Comprehensive company profiles of major players.

Table of Content TABLE OF CONTENTS CHAPTER 1 INTRODUCTION 2

Global Markets and Technologies for Pandemic Control (From Issuu)

Page 2/22


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! REASONS FOR DOING THE STUDY 2 SCOPE OF REPORT 2 METHODOLOGY/INFORMATION SOURCES 3 INTENDED AUDIENCE 3 ANALYST CREDENTIALS 3 RELATED BCC REPORTS 4 BCC ONLINE SERVICES 4 DISCLAIMER 4 CHAPTER 2 SUMMARY 6 SUMMARY TABLE PROJECTED MARKET FOR PANDEMIC INFECTIOUS DISEASE PRODUCTS, BY DISEASE TYPE, THROUGH 2017 ($ MILLIONS) 7 SUMMARY FIGURE PROJECTED MARKET FOR PANDEMIC INFECTIOUS DISEASE PRODUCTS, BY REGION, 2012 AND 2017 (%) 7 CHAPTER 3 OVERVIEW 10 PATHOGENIC MICROBES AND INFECTIOUS DISEASES RECOGNIZED BETWEEN 1973 AND 2009 10 TABLE 1 DISEASE-CAUSING BACTERIA, PARASITES, AND VIRUSES IDENTIFIED BETWEEN 1973 AND 2009 10 FACTORS IN THE EMERGENCE OF INFECTIOUS DISEASES 11 HUMAN DEMOGRAPHICS AND BEHAVIOR 12 TECHNOLOGY 12 THE ROLE OF NEEDLES 12 ECONOMIC DEVELOPMENT AND LAND USE 12 INTERNATIONAL TRAVEL 13 MICROBIAL ADAPTATION 13 ANTIBIOTIC DEVELOPMENT 13 TABLE 2 HISTORY OF ANTIBIOTIC DISCOVERY AND APPROVAL, 1935-2003 13 CLASSIFYING VIRAL OUTBREAKS, EPIDEMICS AND PANDEMICS 14 TABLE 3 CDC'S SIX PHASES OF CLASSIFICATION OF VIRAL PANDEMICS 14 CURRENT AND POTENTIAL EPIDEMICS WITH PANDEMIC POTENTIAL 14 TABLE 4 MAJOR INFECTIOUS DISEASES WITH TYPE OF DISEASE, NUMBER OF CASES, AND POTENTIAL AS A PANDEMIC, 2011 15 CURRENT AND POTENTIAL PANDEMICS 16 CURRENT TECHNOLOGIES FOR ADDRESSING POTENTIAL PANDEMIC THREATS 16 TABLE 5 TECHNOLOGIES TO ADDRESS POTENTIAL PANDEMIC THREATS 17 BIOLOGICAL WEAPONS FOR TERRORISM 17 TABLE 6 DISEASES THAT COULD BE OR HAVE BEEN WEAPONIZED 18 THE NEXT PANDEMIC 18 TYPES OF ZOONOTIC VIRUSES 19 A BRIEF HISTORY OF GLOBAL PANDEMICS 19 BUBONIC PLAGUE (1300 TO PRESENT) 19 CHOLERA (1916 TO 1966) 20 THE SPANISH INFLUENZA PANDEMIC (1918) 20

Global Markets and Technologies for Pandemic Control (From Issuu)

Page 3/22


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! ASIAN FLU PANDEMIC (1957 TO 1958) 20 HIV/AIDS PANDEMIC (1980 TO PRESENT) 21 INFLUENZA A-H1N1 (2009 TO PRESENT) 21 MALARIA (2700 BC TO PRESENT) 21 SEVERE ACUTE RESPIRATORY SYNDROME (SARS) (2002 TO 2003) 22 SMALLPOX (15TH CENTURY TO 1979) 22 TUBERCULOSIS (4000 BC TO PRESENT) 22 TREATMENTS FOR INFECTIOUS DISEASES 23 PREVENTION 23 VACCINATION 23 PHARMACEUTICAL TREATMENTS 23 OPPORTUNITIES TO FIGHT POTENTIAL PANDEMIC INFECTIOUS DISEASES 24 BIOINFORMATION AND REMOTE SENSING MARKET 24 MERGERS AND ACQUISITIONS 24 TABLE 7 SELECTED MERGERS AND ACQUISITIONS, 2008-2012 ($ MILLIONS) 25 CHAPTER 4 VACCINES, DIAGNOSTIC TESTING, AND PHARMACEUTICAL MARKETS FOR INFECTIOUS DISEASES 27 VACCINES 27 TABLE 8 MAJOR MANUFACTURERS OF VACCINES FOR CURRENT AND POTENTIAL PANDEMICS 28 TYPES OF DIAGNOSTIC TESTING 28 FLUORESCENT IMMUNOASSAY (FIA) 29 Direct Fluorescent Antibody Testing 29 Indirect Fluorescent Antibody Testing 29 Chemiluminescent Microparticle Immunoassay (CIA) 29 Chemiluminescent Microparticle Immunoassay (CIA) 29 ENZYME IMMUNOASSAY 30 Basic EIA 30 Enzyme-linked Immunosorbent Assay (ELISA) 30 GENE PROBE ANALYSIS 31 Polymerase Chain Reaction Amplification 31 Nucleic Acid Amplification Test (NAT) 31 Transcription-Mediated Amplification (TMA) 32 Nucleic Acid Sequence-Based Amplification (NASBA) 32 MARKET ANALYSIS, BY DISEASE 32 HEPATITIS B AND C 32 Diagnostic Product Market 33 TABLE 9 HEPATITIS B AND C DIAGNOSTIC PRODUCT MARKET BY TYPE OF TEST, 2011 ($ MILLIONS/%) 33 TABLE 10 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HEPATITIS B AND C, 2012 33 Automated Infectious Disease Testing for Hepatitis 35 Treatment Market 35 TABLE 11 HEPATITIS B AND C TREATMENT MANUFACTURER MARKET STANDING, BY REVENUE, 2011 ($ MILLIONS) 36

Global Markets and Technologies for Pandemic Control (From Issuu)

Page 4/22


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! FIGURE 1 TOP PHARMACEUTICAL MANUFACTURERS IN THE HEPATITIS MARKET AND THEIR MARKET SHARE, 2011 (%) 36 Vaccines and Medications for Hepatitis 37 TABLE 12 VACCINES AND MEDICATIONS FOR THE TREATMENT OF HEPATITIS, 2012 37 HIV/AIDS 38 Diagnostic Market 38 TABLE 13 HIV DIAGNOSTIC PRODUCT MARKET SHARE, 2011 ($ MILLIONS/%) 38 TABLE 14 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HIV/AIDS, 2012 38 Treatments 39 TABLE 15 HIV LIFE CYCLE 40 Nucleoside Reverse Transcriptase Inhibitors (NRTI) 40 Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) 40 Protease Inhibitors (PI) 40 Entry Inhibitors 41 Integrase Inhibitors 41 Multi-class Combination 41 Generic Treatments 41 TABLE 16 FDA-APPROVED GENERIC DRUGS FOR TREATMENT OF HIV, 2004 TO 2012 41 Brand Name HIV Treatments 42 TABLE 17 CURRENTLY APPROVED PHARMACEUTICAL PRODUCTS FOR TREATMENT OF HIV/AIDS, 2012 43 BRANDED TREATMENT MARKET, BY MAJOR MANUFACTURER 44 TABLE 18 HIV TREATMENT MARKET BY MANUFACTURER, 2011 ($ MILLIONS) 44 FIGURE 2 MARKET SHARE FOR BRANDED HIV DRUGS BY MANUFACTURER, 2011 (%) 44 INFLUENZA 45 Pandemic Influenza (H1N1) 46 Diagnostic Products 46 TABLE 19 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF PANDEMIC INFLUENZA, 2012 46 Pharmaceutical Products 46 TABLE 20 CURRENT PHARMACEUTICALS APPROPRIATE FOR TREATMENT OF PANDEMIC INFLUENZA 47 MALARIA 47 Mosquito Netting 47 TABLE 21 WHO RECOMMENDED MOSQUITO NETTING, 2012 48 Diagnosis of Malaria 48 TABLE 22 AVAILABLE MALARIA DIAGNOSTIC METHODS 49 Diagnostic Tests of Malaria 49 TABLE 23 CURRENT RAPID DIAGNOSTIC TESTS FOR DETECTION OF MALARIA 49 Pharmaceutical Treatments for Malaria 50 TABLE 24 PHARMACEUTICAL PRODUCTS USED TO TREAT MALARIA, 2012 51 TUBERCULOSIS 51 Diagnostic Products 51

Global Markets and Technologies for Pandemic Control (From Issuu)

Page 5/22


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! TABLE 25 CURRENT DIAGNOSTIC TESTS FOR DETECTION OF TUBERCULOSIS, 2012 52 Pharmaceutical Products 52 TABLE 26 DRUGS USED TO TREAT TB 52 CHAPTER 5 DISEASE OVERVIEW 55 TABLE 27 CAUSATIVE ORGANISMS FOR PANDEMIC DISEASES 55 ANTHRAX 55 OVERVIEW 55 RISK FACTORS 55 INCIDENCE 56 DIAGNOSTIC PROCEDURES 56 TREATMENTS 56 TABLE 28 VACCINES AND MEDICATIONS FOR THE TREATMENT OF ANTHRAX, 2012 56 CHOLERA 57 OVERVIEW 57 RISK FACTORS 57 INCIDENCE 57 DIAGNOSTIC PROCEDURES 57 TABLE 29 CURRENT DIAGNOSTIC TESTS FOR CHOLERA 57 TREATMENT 58 HEPATITIS B AND C 58 OVERVIEW 58 RISK FACTORS 59 INCIDENCE 59 Hepatitis in the U.S. 59 Hepatitis C in the U.S. 59 Hepatitis in Canada 59 Hepatitis B and C in EMRA 59 Hepatitis in Africa 60 Hepatitis in Russia, Eurasia 60 Hepatitis in Japan 61 Hepatitis in China 61 Hepatitis in India 61 Hepatitis in Australia 61 TREATMENTS 61 HIV/AIDS 61 OVERVIEW 61 TABLE 30 CDC CLASSIFICATION OF HIV INFECTION 62 RISK FACTORS 63 INCIDENCE/MORTALITY 63 HIV in the U.S. 63 HIV and Women in the U.S. 64 HIV in Canada 64 HIV in Latin and South America 64 HIV Treatment in Central/South America 64

Global Markets and Technologies for Pandemic Control (From Issuu)

Page 6/22


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! HIV/AIDS in the EMRA 65 HIV in Africa 65 Access to Therapeutics in Africa 65 Russia, Eastern Europe, Central Asia 66 HIV Treatments in the Region 66 HIV in the Middle East 66 HIV in Sub-Saharan Africa 66 HIV/AIDS in Asia 67 HIV in Japan 67 HIV in India 67 HIV Testing/Treatment in India 67 HIV in China 68 HIV Testing and Treatment in China 68 Estimated Active Pharmaceutical Ingredients Needed 69 TABLE 31 PROJECTED NEED FOR API TO MEET CORE ARV PRODUCT REQUIREMENTS, 2011 AND 2015 69 INFLUENZA 69 OVERVIEW 69 Vaccines 69 New Production Techniques for Developing Influenza Vaccines 70 H1N1 70 H5N1 70 Mutations that Transform H5N1 into Pandemic Influenza 70 Pandemic Risk 71 Risk Factors 71 Incidence/Mortality 72 MALARIA 72 OVERVIEW 72 RISK FACTORS 72 Biological Characteristics 72 INCIDENCE/MORTALITY 73 TREATMENT MARKET 73 SEVERE ACUTE RESPIRATORY SYNDROME (SARS) 73 OUTBREAK LOCALES 73 INFECTION AND TRANSMISSION 74 TREATMENT 74 TUBERCULOSIS 74 OVERVIEW 74 RISK FACTORS 74 INCIDENCE/MORTALITY 75 HEMORRHAGIC FEVERS 75 ARENAVIRUSES 76 BUNYAVIRUSES 76 FILOVIRUSES 76 FLAVIVIRUSES 77 RISK 77 PANDEMIC POTENTIAL FOR HEMORRHAGIC VIRUSES 77

Global Markets and Technologies for Pandemic Control (From Issuu)

Page 7/22


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! CHAPTER 6 VIRAL PANDEMIC THREATS AND TREATMENTS 80 WHAT IS A VIRUS' 80 PROJECTED GLOBAL MARKET FOR VACCINES, DIAGNOSTICS AND PHARMACEUTICALS 80 TABLE 32 PROJECTED GLOBAL MARKET FOR VIRAL HIV AND HEPATITIS DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 80 GLOBAL DIAGNOSTIC MARKET FOR HIV AND HEPATITIS 81 MARKET FOR VIRAL DISEASE DIAGNOSTIC PRODUCTS 81 TABLE 33 PROJECTED GLOBAL MARKET FOR DIAGNOSTIC PRODUCTS USED TO DETECT HIV AND HEPATITIS PANDEMIC DISEASES, THROUGH 2017 ($ MILLIONS) 81 FIGURE 3 PROJECTED GLOBAL MARKET FOR DIAGNOSTIC PRODUCTS USED TO DETECT HIV AND HEPATITIS PANDEMIC DISEASES, 2012 AND 2017 (%) 81 VIRAL PANDEMIC PHARMACEUTICAL PRODUCTS, BY DISEASE 82 TABLE 34 PROJECTED GLOBAL MARKET FOR VIRAL PANDEMIC PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 83 FIGURE 4 GLOBAL MARKET FOR VIRAL PANDEMIC PHARMACEUTICAL PRODUCTS, 2012 AND 2017 (%) 83 HEPATITIS 84 TABLE 35 HEPATITIS CHARACTERISTICS BY TYPE 84 TABLE 36 PROJECTED GLOBAL MARKET FOR HEPATITIS DIAGNOSTIC PRODUCTS, THROUGH 2017 ($ MILLIONS) 85 TABLE 37 PROJECTED GLOBAL MARKET FOR HEPATITIS VACCINE AND PHARMACEUTICALS, THROUGH 2017 ($ MILLIONS) 86 HEPATITIS A 86 TABLE 38 PROJECTED REVENUE FROM HEPATITIS A TREATMENTS, THROUGH 2017 ($ MILLIONS) 86 HEPATITIS B 87 TABLE 39 PROJECTED GLOBAL REVENUE FROM HEPATITIS PHARMACEUTICALS AND VACCINATIONS, THROUGH 2017 ($ MILLIONS) 87 HEPATITIS C 87 TABLE 40 PROJECTED GLOBAL REVENUE FROM HEPATITIS C PHARMACEUTICAL TREATMENTS, THROUGH 2017 ($ MILLIONS) 87 FIGURE 5 MARKET SHARES FOR HEPATITIS C TREATMENTS, 2010 (%) 88 REGIONAL ANALYSIS 88 TABLE 41 PROJECTED GLOBAL MARKET FOR VIRAL PANDEMIC DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, BY REGION, THROUGH 2017 ($ MILLIONS) 89 PROJECTED GLOBAL MARKET FOR VIRAL PANDEMIC DIAGNOSTIC PRODUCTS, BY REGION 89 TABLE 42 PROJECTED GLOBAL MARKET FOR VIRAL PANDEMIC DIAGNOSTIC PRODUCTS, THROUGH 2017 ($ MILLIONS) 89 FIGURE 6 GLOBAL PANDEMIC VIRAL INFECTIOUS DISEASE DIAGNOSTIC

Global Markets and Technologies for Pandemic Control (From Issuu)

Page 8/22


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! MARKET, 2012 AND 2017 (%) 89 TABLE 43 PROJECTED GLOBAL MARKET FOR PANDEMIC PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 91 FIGURE 7 GLOBAL PANDEMIC PHARMACEUTICAL MARKET, 2012 AND 2017 (%) 91 AMERICAS 92 TABLE 44 PROJECTED AMERICAS MARKET FOR VIRAL PANDEMIC DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 92 TABLE 45 PROJECTED MARKET FOR VIRAL PANDEMIC DIAGNOSTIC PRODUCTS IN THE AMERICAS, THROUGH 2017 ($ MILLIONS) 93 TABLE 46 PROJECTED MARKET FOR VIRAL PANDEMIC PHARMACEUTICAL PRODUCTS IN THE AMERICAS, THROUGH 2017 ($ MILLIONS) 93 EMRA 93 TABLE 47 PROJECTED EMRA MARKET FOR VIRAL PANDEMIC DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 94 DIAGNOSTIC MARKET IN EMRA 94 TABLE 48 PROJECTED EMRA MARKET FOR VIRAL PANDEMIC DIAGNOSTIC PRODUCTS, THROUGH 2017 ($ MILLIONS) 94 TABLE 49 PROJECTED EMRA MARKET FOR VIRAL PANDEMIC PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 95 ASIA 95 TABLE 50 PROJECTED ASIAN MARKET FOR VIRAL PANDEMIC DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 95 DIAGNOSTIC PRODUCTS IN ASIA 95 TABLE 51 PROJECTED MARKET FOR VIRAL PANDEMIC DIAGNOSTIC PRODUCTS IN ASIA, THROUGH 2017 ($ MILLIONS) 96 FIGURE 8 MARKET FOR PANDEMIC DIAGNOSTIC PRODUCTS IN ASIA 2012 AND 2017 (%) 96 TABLE 52 PROJECTED MARKET FOR VIRAL PANDEMIC PHARMACEUTICAL PRODUCTS IN ASIA, THROUGH 2017 ($ MILLIONS) 97 OPPORTUNITIES IN THE VIRAL PANDEMIC INFECTIOUS DISEASE DIAGNOSIS AND TREATMENT MARKET 97 OPPORTUNITIES IN THE HIV/AIDS MARKET 97 Diagnostics 97 Pharmaceuticals 98 Immediate Term Priorities 99 Medium Term Priorities 99 OPPORTUNITIES IN THE HEPATITIS MARKET 100 Pharmaceutical Opportunities in the Hepatitis Market 100 CHAPTER 7 BACTERIAL PANDEMIC THREATS AND TREATMENTS 102 ANTIBACTERIAL RESISTANCE 102 THE MICROBIOLOGY OF BACTERIAL RESISTANCE 102 MECHANISMS OF RESISTANCE 103 METHODS OF RESISTANCE 103

Global Markets and Technologies for Pandemic Control (From Issuu)

Page 9/22


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! Beta-Lactamase Production 103 Importing Resistance from Other Organisms 104 Alteration of Binding Sites to Circumvent Anti-Infective Effectiveness 105 Antibiotic Discharge 105 PRIMARY REASONS FOR ANTIBIOTIC RESISTANCE 105 BROAD-SPECTRUM PRESCRIPTIONS 105 PATIENT PRESSURE 106 SURVEILLANCE OF MICROBIAL RESISTANCE TO ANTIBIOTICS 106 RESISTANCE BY CLASS OF ANTIBIOTIC 106 TABLE 53 ANTIBIOTIC RESISTANT ORGANISMS AND DRUG CLASSES AFFECTED 106 INCIDENCES OF ANTIBIOTIC RESISTANCE 107 ANTIBIOTIC RESISTANCE IN EUROPE 107 MRSA INFECTIONS IN MALAYSIA 107 ANTIBIOTIC RESISTANCE IN THE U.S. 107 VANCOMYCIN-RESISTANT ENTEROCOCCUS (VRE) 107 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 108 CLOSTRIDIUM DIFFICILE (C. DIFFICILE) 108 TUBERCULOSIS (TB) 108 TABLE 54 PROJECTED GLOBAL MARKET FOR TB DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 ($ MILLIONS) 108 EPIDEMIOLOGY OF TB 109 GEOGRAPHIC PREVALENCE 109 FINANCING CONTROL EFFORTS 110 DIAGNOSING TB 110 Smear Microscopy 110 Phage-based Diagnostics 110 Nucleic Acid Amplification Technologies (NAAT) 110 TABLE 55 PROJECTED GLOBAL MARKET FOR TB DIAGNOSTIC TESTS, THROUGH 2017 ($ MILLIONS) 111 PHARMACEUTICAL TREATMENTS FOR TB 111 TABLE 56 CURRENTLY AVAILABLE TREATMENTS FOR TB WITH BRAND NAME, GENERIC NAME AND MANUFACTURER, 2012 111 MARKET FOR TB PHARMACEUTICAL TREATMENTS 112 TABLE 57 PROJECTED GLOBAL MARKET FOR TB PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 112 REGIONAL ANALYSIS 112 TABLE 58 PROJECTED GLOBAL MARKET FOR DIAGNOSTIC TB PRODUCTS BY REGION, THROUGH 2017 ($ MILLIONS) 113 TABLE 59 PROJECTED GLOBAL MARKET FOR TB PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 ($ MILLIONS) 113 AMERICAS 113 TABLE 60 PROJECTED AMERICAS MARKET FOR TB DIAGNOSTIC PRODUCTS THROUGH 2017 ($ MILLIONS) 114 TABLE 61 PROJECTED AMERICAS MARKET FOR TB PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 114 EMRA 114

Global Markets and Technologies for Pandemic Control (From Issuu)

Page 10/22


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! TABLE 62 PROJECTED EMRA MARKET FOR TB DIAGNOSTIC PRODUCTS, THROUGH 2017 ($ MILLIONS) 115 TABLE 63 PROJECTED EMRA MARKET FOR TB PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 115 ASIA 115 TABLE 64 PROJECTED ASIAN MARKET FOR TB DIAGNOSTIC PRODUCTS, THROUGH 2017 ($ MILLIONS) 116 TABLE 65 PROJECTED ASIAN MARKET FOR TB PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 116 OPPORTUNITIES IN THE TUBERCULOSIS MARKET 116 PREVENTION 116 TABLE 66 CURRENT TB VACCINES IN DEVELOPMENT 117 DIAGNOSTICS 117 TREATMENT 117 TABLE 67 PHARMACEUTICALS IN DEVELOPMENT FOR THE TREATMENT OF TB, 2012 118 CHAPTER 8 PARASITIC PANDEMIC THREATS AND TREATMENTS 120 CLIMATE CHANGE AND VECTOR-BORNE DISEASES 120 MALARIA 120 TABLE 68 ESTIMATED 2010 GLOBAL MALARIA CASES AND DEATHS, WITH RATE OF DECREASE OF MALARIA DEATHS BY REGION* SINCE 2000 120 Cause of Malaria 121 TABLE 69 PROJECTED GLOBAL MARKET FOR MALARIA PREVENTION, DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 ($ MILLIONS) 121 Interventional Techniques to Minimize Exposure to Malarial Vectors 122 TABLE 70 PROJECTED GLOBAL MARKET FOR INSECTICIDE-TREATED NETS, THROUGH 2017 ($ MILLIONS) 122 Diagnosis of Malaria 122 TABLE 71 PROJECTED GLOBAL MARKET FOR MALARIAL DIAGNOSTIC PRODUCTS, THROUGH 2017 ($ MILLIONS) 123 Treatment of Malaria 123 TABLE 72 PROJECTED GLOBAL MARKET FOR MALARIA DRUG TREATMENTS, THROUGH 2017 ($ MILLIONS) 123 Regional Analysis 123 TABLE 73 PROJECTED GLOBAL MARKET FOR MALARIAL PANDEMIC PREVENTION, DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 ($ MILLIONS) 124 The Americas 124 TABLE 74 PROJECTED AMERICAS MARKET FOR MALARIA PREVENTATIVE, DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS THROUGH 2017 ($ MILLIONS) 124 TABLE 75 MALARIAL PREVENTION PRODUCT MARKET IN THE AMERICAS BY

Global Markets and Technologies for Pandemic Control (From Issuu)

Page 11/22


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! REGION, THROUGH 2017 ($ MILLIONS) 125 TABLE 76 MALARIAL DIAGNOSTIC PRODUCT MARKET IN THE AMERICAS BY REGION, THROUGH 2017 ($ MILLIONS) 125 TABLE 77 MALARIAL PHARMACEUTICAL PRODUCT MARKET IN THE AMERICAS BY REGION, THROUGH 2017 ($ MILLIONS) 126 EMRA 126 TABLE 78 PROJECTED EMRA MARKET FOR MALARIAL PREVENTATIVE, DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS THROUGH 2017 ($ MILLIONS) 126 TABLE 79 MALARIAL PREVENTATIVE PRODUCT MARKET IN THE EMRA BY REGION, THROUGH 2017 ($ MILLIONS) 127 TABLE 80 MALARIAL DIAGNOSTIC PRODUCT MARKET IN THE EMRA BY REGION, THROUGH 2017 ($ MILLIONS) 127 TABLE 81 MALARIAL PHARMACEUTICAL PRODUCT MARKET IN THE EMRA BY REGION, THROUGH 2017 ($ MILLIONS) 128 Asia 128 TABLE 82 PROJECTED ASIA MARKET FOR MALARIA PREVENTATIVE, DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 ($ MILLIONS) 128 TABLE 83 MALARIAL PREVENTION PRODUCT MARKET IN ASIA BY REGION, THROUGH 2017 ($ MILLIONS) 129 TABLE 84 MALARIAL DIAGNOSTIC PRODUCT MARKET IN ASIA BY REGION, THROUGH 2017 ($ MILLIONS) 129 TABLE 85 MALARIAL PHARMACEUTICAL PRODUCT MARKET IN ASIA BY REGION, THROUGH 2017 ($ MILLIONS) 130 OPPORTUNITIES IN THE MALARIAL DISEASE MARKET 130 Diagnostic Testing 130 Pharmaceutical Products 130 CHAPTER 9 REGULATIONS 132 CREATING DRUG TREATMENTS 132 TABLE 86 PROCESS OF CREATING DRUG TREATMENTS IN THE U.S. 132 REGIONAL REGULATIONS 133 THE AMERICAS 133 Canada 133 EMA 134 Diagnostic Products in EU 134 ASIA 134 Japan 134 Diagnostic Regulations 135 Pharmaceutical Regulations 135 China 135 India 135 CHAPTER 10 PHARMACEUTICAL TREATMENT PIPELINE 138

Global Markets and Technologies for Pandemic Control (From Issuu)

Page 12/22


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! EMERGING TRENDS IN DIAGNOSTIC PRODUCTS 138 ANTIBIOTIC-RESISTANT INFECTIONS 138 EMERGING TRENDS IN PHARMACEUTICAL PRODUCTS 138 HIV/AIDS 138 Gilead Sciences 139 GlaxoSmithKline 139 HEPATITIS 139 Gilead Sciences 139 Janssen Pharmaceuticals/Tibotec Pharmaceuticals 140 Merck 140 Roche 140 Boehringer Ingelheim 140 Vertex Pharmaceuticals 141 INFLUENZA 141 VaxInnate 141 PHARMACEUTICAL TREATMENT PRODUCT PIPELINE 141 TABLE 87 PANDEMIC DISEASE PHARMACEUTICAL PRODUCT PIPELINE, 2012 141 CHAPTER 11 PATENT ANALYSIS 149 PHARMACEUTICAL PATENTS ISSUED BY COMPANY, APPROVAL DATE AND DISEASE 149 TABLE 88 PANDEMIC PHARMACEUTICAL AND VACCINE PATENTS (FEBRUARY 2006-DECEMBER 2012) 150 DIAGNOSTIC PATENTS ISSUED BY COMPANY, APPROVAL DATE AND DISEASE 154 TABLE 89 PANDEMIC DIAGNOSTIC PATENTS (MARCH 2005 THROUGH DECEMBER 2012) 154 PATENTS ISSUED BY COMPANY 155 TABLE 90 PANDEMIC PHARMACEUTICAL AND VACCINE PRODUCT PATENTS (JANUARY 2005 THROUGH DECEMBER 2012) 155 TABLE 91 PANDEMIC DIAGNOSTIC PRODUCT PATENTS (JANUARY 2005 THROUGH DECEMBER 2012) 156 PATENTS ISSUED BY COUNTRY 157 TABLE 92 PANDEMIC PRODUCT DIAGNOSIS AND TREATMENT PATENTS, BY COUNTRY (JANUARY 2005 THROUGH DECEMBER 2012) 157 PATENTS ISSUED, BY DISEASE 157 TABLE 93 PATENTS ISSUED FOR DIAGNOSIS AND TREATMENT OF PANDEMIC DISEASES (MARCH 2005 THROUGH OCTOBER 2012) 158 FIGURE 9 DIAGNOSTIC AND PHARMACEUTICAL PATENTS ISSUED (BETWEEN MARCH 2005 AND DECEMBER 2012) (%) 158 CHAPTER 12 COMPANY DIRECTORY 161 ABBOTT LABORATORIES 161 TABLE 94 ABBOTT PHARMACEUTICAL PRODUCTS 161 TABLE 95 ABBOTT DIAGNOSTIC PRODUCTS 161 ALERE 161

Global Markets and Technologies for Pandemic Control (From Issuu)

Page 13/22


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! TABLE 96 ALERE DIAGNOSTIC PRODUCTS 162 ALFA SCIENTIFIC DESIGNS 162 TABLE 97 ALFA SCIENTIFIC DESIGNS DIAGNOSTIC PRODUCTS 163 ANADYS PHARMACEUTICALS (SEE ROCHE) 163 ATLAS LINK BIOTECH CO, LTD 163 TABLE 98 ATLAS LINK BIOTECH DIAGNOSTIC PRODUCTS 163 BAXTER HEALTHCARE 163 TABLE 99 BAXTER PHARMACEUTICAL PRODUCTS 164 BAYER AG 164 TABLE 100 BAYER PHARMACEUTICAL PRODUCTS 164 BIO-RAD LABORATORIES 164 TABLE 101 BIO-RAD DIAGNOSTIC PRODUCTS 165 BOEHRINGER INGELHEIM GMBH 165 TABLE 102 BOEHRINGER INGELHEIM PHARMACEUTICAL PRODUCTS 165 BRISTOL-MYERS SQUIBB COMPANY 166 TABLE 103 BRISTOL-MYERS SQUIBB PHARMACEUTICAL PRODUCTS 166 CREATIVE DIAGNOSTICS 166 TABLE 104 CREATIVE DIAGNOSTICS DIAGNOSTIC PRODUCTS 167 DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS, INC 167 TABLE 105 DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS DIAGNOSTIC PRODUCTS 167 DIASORIN 168 TABLE 106 DIAGNOSTIC PRODUCTS 168 EMERGENT BIOSOLUTIONS 168 TABLE 107 PHARMACEUTICAL PRODUCTS 169 ENANTA PHARMACEUTICALS 169 ENZO BIOCHEM 169 TABLE 108 ENZO BIOCHEM DIAGNOSTIC PRODUCTS 169 FIRST DIAGNOSTIC LLC 170 TABLE 109 DIAGNOSTIC PRODUCT 170 GILEAD SCIENCES, INC. 170 TABLE 110 GILEAD SCIENCES PHARMACEUTICAL PRODUCTS 171 GLAXOSMITHKLINE 171 TABLE 111 GSK PHARMACEUTICAL PRODUCTS 171 HOME ACCESS HEALTH, INC 172 TABLE 112 HOME ACCESS HEALTH DIAGNOSTIC PRODUCTS 172 HUMAN GENOME SCIENCES (SEE GLAXOSMITHKLINE) 172 IDENIX PHARMACEUTICALS 172 IMMUNOSTICS 173 TABLE 113 IMMUNOSTICS DIAGNOSTIC PRODUCTS 173 IND DIAGNOSTIC, INC. 173 TABLE 114 IND DIAGNOSTIC PRODUCTS 173 INVERNESS MEDICAL INNOVATIONS (SEE ALERE) 174 JANSSEN THERAPEUTICS (FORMERLY TIBOTEC THERAPEUTICS) 174 TABLE 115 JANSSEN THERAPEUTICS PHARMACEUTICAL PRODUCTS 174 MERCK & COMPANY, INC. 174 TABLE 116 MERCK PHARMACEUTICAL PRODUCTS 175 NOVARTIS PHARMACEUTICAL CORPORATION 175

Global Markets and Technologies for Pandemic Control (From Issuu)

Page 14/22


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! TABLE 117 NOVARTIS DIAGNOSTIC PRODUCTS 176 ORASURE TECHNOLOGIES, INC. 176 TABLE 118 ORASURE DIAGNOSTIC PRODUCTS 176 ORTHO CLINICAL DIAGNOSTICS 176 TABLE 119 ORTHO DIAGNOSTIC PRODUCTS 177 PFIZER, INC. 177 TABLE 120 PFIZER PHARMACEUTICAL PRODUCTS 177 PRINCETON BIOMEDITECH CORPORATION 178 TABLE 121 PRINCETON BIOMEDITECH DIAGNOSTIC PRODUCTS 178 PROTEIN SCIENCES CORPORATION 178 ROCHE LABORATORIES (HOFFMANN-LA ROCHE INC) 179 TABLE 122 ROCHE PHARMACEUTICAL PRODUCTS 179 RIB-X PHARMACEUTICALS 179 ROMARK LABORATORIES 180 SANOFI PASTEUR 180 TABLE 123 SANOFI PASTEUR PHARMACEUTICAL PRODUCTS 180 SCICLONE PHARMACEUTICALS 181 TABLE 124 SCICLONE PHARMACEUTICALS PHARMACEUTICAL PRODUCTS 181 SHANGHAI KEHUA BIO-ENGINEERING CO, LTD 181 TABLE 125 SHANGHAI KEHUA BIO-ENGINEERING DIAGNOSTIC PRODUCTS 181 STANDARD DIAGNOSTICS, INC 182 TABLE 126 STANDARD DIAGNOSTICS DIAGNOSTIC PRODUCTS 182 TRINITY BIOTECH PLC 183 TABLE 127 TRINITY BIOTECH DIAGNOSTIC PRODUCTS 183 VERTEX PHARMACEUTICALS 183 TABLE 128 VERTEX PHARMACEUTICALS PHARMACEUTICAL PRODUCTS 183 VIIV HEALTHCARE 184 TABLE 129 VIIV HEALTHCARE PHARMACEUTICAL PRODUCTS 184

LIST OF TABLES SUMMARY TABLE PROJECTED MARKET FOR PANDEMIC INFECTIOUS DISEASE PRODUCTS, BY DISEASE TYPE, THROUGH 2017 ($ MILLIONS) 7 TABLE 1 DISEASE-CAUSING BACTERIA, PARASITES, AND VIRUSES IDENTIFIED BETWEEN 1973 AND 2009 10 TABLE 2 HISTORY OF ANTIBIOTIC DISCOVERY AND APPROVAL, 1935-2003 13 TABLE 3 CDC'S SIX PHASES OF CLASSIFICATION OF VIRAL PANDEMICS 14 TABLE 4 MAJOR INFECTIOUS DISEASES WITH TYPE OF DISEASE, NUMBER OF CASES, AND POTENTIAL AS A PANDEMIC, 2011 15 TABLE 5 TECHNOLOGIES TO ADDRESS POTENTIAL PANDEMIC THREATS 17 TABLE 6 DISEASES THAT COULD BE OR HAVE BEEN WEAPONIZED 18 TABLE 7 SELECTED MERGERS AND ACQUISITIONS, 2008-2012 ($ MILLIONS) 25 TABLE 8 MAJOR MANUFACTURERS OF VACCINES FOR CURRENT AND POTENTIAL PANDEMICS 28 TABLE 9 HEPATITIS B AND C DIAGNOSTIC PRODUCT MARKET BY TYPE OF TEST, 2011 ($ MILLIONS/%) 33

Global Markets and Technologies for Pandemic Control (From Issuu)

Page 15/22


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! TABLE 10 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HEPATITIS B AND C, 2012 33 TABLE 11 HEPATITIS B AND C TREATMENT MANUFACTURER MARKET STANDING, BY REVENUE, 2011 ($ MILLIONS) 36 TABLE 12 VACCINES AND MEDICATIONS FOR THE TREATMENT OF HEPATITIS, 2012 37 TABLE 13 HIV DIAGNOSTIC PRODUCT MARKET SHARE, 2011 ($ MILLIONS/%) 38 TABLE 14 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HIV/AIDS, 2012 38 TABLE 15 HIV LIFE CYCLE 40 TABLE 16 FDA-APPROVED GENERIC DRUGS FOR TREATMENT OF HIV, 2004 TO 2012 41 TABLE 17 CURRENTLY APPROVED PHARMACEUTICAL PRODUCTS FOR TREATMENT OF HIV/AIDS, 2012 43 TABLE 18 HIV TREATMENT MARKET BY MANUFACTURER, 2011 ($ MILLIONS) 44 TABLE 19 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF PANDEMIC INFLUENZA, 2012 46 TABLE 20 CURRENT PHARMACEUTICALS APPROPRIATE FOR TREATMENT OF PANDEMIC INFLUENZA 47 TABLE 21 WHO RECOMMENDED MOSQUITO NETTING, 2012 48 TABLE 22 AVAILABLE MALARIA DIAGNOSTIC METHODS 49 TABLE 23 CURRENT RAPID DIAGNOSTIC TESTS FOR DETECTION OF MALARIA 49 TABLE 24 PHARMACEUTICAL PRODUCTS USED TO TREAT MALARIA, 2012 51 TABLE 25 CURRENT DIAGNOSTIC TESTS FOR DETECTION OF TUBERCULOSIS, 2012 52 TABLE 26 DRUGS USED TO TREAT TB 52 TABLE 27 CAUSATIVE ORGANISMS FOR PANDEMIC DISEASES 55 TABLE 28 VACCINES AND MEDICATIONS FOR THE TREATMENT OF ANTHRAX, 2012 56 TABLE 29 CURRENT DIAGNOSTIC TESTS FOR CHOLERA 57 TABLE 30 CDC CLASSIFICATION OF HIV INFECTION 62 TABLE 31 PROJECTED NEED FOR API TO MEET CORE ARV PRODUCT REQUIREMENTS, 2011 AND 2015 69 TABLE 32 PROJECTED GLOBAL MARKET FOR VIRAL HIV AND HEPATITIS DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 80 TABLE 33 PROJECTED GLOBAL MARKET FOR DIAGNOSTIC PRODUCTS USED TO DETECT HIV AND HEPATITIS PANDEMIC DISEASES, THROUGH 2017 ($ MILLIONS) 81 TABLE 34 PROJECTED GLOBAL MARKET FOR VIRAL PANDEMIC PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 83 TABLE 35 HEPATITIS CHARACTERISTICS BY TYPE 84 TABLE 36 PROJECTED GLOBAL MARKET FOR HEPATITIS DIAGNOSTIC PRODUCTS, THROUGH 2017 ($ MILLIONS) 85 TABLE 37 PROJECTED GLOBAL MARKET FOR HEPATITIS VACCINE AND PHARMACEUTICALS, THROUGH 2017 ($ MILLIONS) 86 TABLE 38 PROJECTED REVENUE FROM HEPATITIS A TREATMENTS, THROUGH 2017 ($ MILLIONS) 86

Global Markets and Technologies for Pandemic Control (From Issuu)

Page 16/22


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! TABLE 39 PROJECTED GLOBAL REVENUE FROM HEPATITIS PHARMACEUTICALS AND VACCINATIONS, THROUGH 2017 ($ MILLIONS) 87 TABLE 40 PROJECTED GLOBAL REVENUE FROM HEPATITIS C PHARMACEUTICAL TREATMENTS, THROUGH 2017 ($ MILLIONS) 87 TABLE 41 PROJECTED GLOBAL MARKET FOR VIRAL PANDEMIC DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, BY REGION, THROUGH 2017 ($ MILLIONS) 89 TABLE 42 PROJECTED GLOBAL MARKET FOR VIRAL PANDEMIC DIAGNOSTIC PRODUCTS, THROUGH 2017 ($ MILLIONS) 89 TABLE 43 PROJECTED GLOBAL MARKET FOR PANDEMIC PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 91 TABLE 44 PROJECTED AMERICAS MARKET FOR VIRAL PANDEMIC DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 92 TABLE 45 PROJECTED MARKET FOR VIRAL PANDEMIC DIAGNOSTIC PRODUCTS IN THE AMERICAS, THROUGH 2017 ($ MILLIONS) 93 TABLE 46 PROJECTED MARKET FOR VIRAL PANDEMIC PHARMACEUTICAL PRODUCTS IN THE AMERICAS, THROUGH 2017 ($ MILLIONS) 93 TABLE 47 PROJECTED EMRA MARKET FOR VIRAL PANDEMIC DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 94 TABLE 48 PROJECTED EMRA MARKET FOR VIRAL PANDEMIC DIAGNOSTIC PRODUCTS, THROUGH 2017 ($ MILLIONS) 94 TABLE 49 PROJECTED EMRA MARKET FOR VIRAL PANDEMIC PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 95 TABLE 50 PROJECTED ASIAN MARKET FOR VIRAL PANDEMIC DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 95 TABLE 51 PROJECTED MARKET FOR VIRAL PANDEMIC DIAGNOSTIC PRODUCTS IN ASIA, THROUGH 2017 ($ MILLIONS) 96 TABLE 52 PROJECTED MARKET FOR VIRAL PANDEMIC PHARMACEUTICAL PRODUCTS IN ASIA, THROUGH 2017 ($ MILLIONS) 97 TABLE 53 ANTIBIOTIC RESISTANT ORGANISMS AND DRUG CLASSES AFFECTED 106 TABLE 54 PROJECTED GLOBAL MARKET FOR TB DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 ($ MILLIONS) 108 TABLE 55 PROJECTED GLOBAL MARKET FOR TB DIAGNOSTIC TESTS, THROUGH 2017 ($ MILLIONS) 111 TABLE 56 CURRENTLY AVAILABLE TREATMENTS FOR TB WITH BRAND NAME, GENERIC NAME AND MANUFACTURER, 2012 111 TABLE 57 PROJECTED GLOBAL MARKET FOR TB PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 112 TABLE 58 PROJECTED GLOBAL MARKET FOR DIAGNOSTIC TB PRODUCTS BY REGION, THROUGH 2017 ($ MILLIONS) 113 TABLE 59 PROJECTED GLOBAL MARKET FOR TB PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 ($ MILLIONS) 113 TABLE 60 PROJECTED AMERICAS MARKET FOR TB DIAGNOSTIC PRODUCTS THROUGH 2017 ($ MILLIONS) 114 TABLE 61 PROJECTED AMERICAS MARKET FOR TB PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 114 TABLE 62 PROJECTED EMRA MARKET FOR TB DIAGNOSTIC PRODUCTS,

Global Markets and Technologies for Pandemic Control (From Issuu)

Page 17/22


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! THROUGH 2017 ($ MILLIONS) 115 TABLE 63 PROJECTED EMRA MARKET FOR TB PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 115 TABLE 64 PROJECTED ASIAN MARKET FOR TB DIAGNOSTIC PRODUCTS, THROUGH 2017 ($ MILLIONS) 116 TABLE 65 PROJECTED ASIAN MARKET FOR TB PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 116 TABLE 66 CURRENT TB VACCINES IN DEVELOPMENT 117 TABLE 67 PHARMACEUTICALS IN DEVELOPMENT FOR THE TREATMENT OF TB, 2012 118 TABLE 68 ESTIMATED 2010 GLOBAL MALARIA CASES AND DEATHS, WITH RATE OF DECREASE OF MALARIA DEATHS BY REGION* SINCE 2000 120 TABLE 69 PROJECTED GLOBAL MARKET FOR MALARIA PREVENTION, DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 ($ MILLIONS) 121 TABLE 70 PROJECTED GLOBAL MARKET FOR INSECTICIDE-TREATED NETS, THROUGH 2017 ($ MILLIONS) 122 TABLE 71 PROJECTED GLOBAL MARKET FOR MALARIAL DIAGNOSTIC PRODUCTS, THROUGH 2017 ($ MILLIONS) 123 TABLE 72 PROJECTED GLOBAL MARKET FOR MALARIA DRUG TREATMENTS, THROUGH 2017 ($ MILLIONS) 123 TABLE 73 PROJECTED GLOBAL MARKET FOR MALARIAL PANDEMIC PREVENTION, DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 ($ MILLIONS) 124 TABLE 74 PROJECTED AMERICAS MARKET FOR MALARIA PREVENTATIVE, DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS THROUGH 2017 ($ MILLIONS) 124 TABLE 75 MALARIAL PREVENTION PRODUCT MARKET IN THE AMERICAS BY REGION, THROUGH 2017 ($ MILLIONS) 125 TABLE 76 MALARIAL DIAGNOSTIC PRODUCT MARKET IN THE AMERICAS BY REGION, THROUGH 2017 ($ MILLIONS) 125 TABLE 77 MALARIAL PHARMACEUTICAL PRODUCT MARKET IN THE AMERICAS BY REGION, THROUGH 2017 ($ MILLIONS) 126 TABLE 78 PROJECTED EMRA MARKET FOR MALARIAL PREVENTATIVE, DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS THROUGH 2017 ($ MILLIONS) 126 TABLE 79 MALARIAL PREVENTATIVE PRODUCT MARKET IN THE EMRA BY REGION, THROUGH 2017 ($ MILLIONS) 127 TABLE 80 MALARIAL DIAGNOSTIC PRODUCT MARKET IN THE EMRA BY REGION, THROUGH 2017 ($ MILLIONS) 127 TABLE 81 MALARIAL PHARMACEUTICAL PRODUCT MARKET IN THE EMRA BY REGION, THROUGH 2017 ($ MILLIONS) 128 TABLE 82 PROJECTED ASIA MARKET FOR MALARIA PREVENTATIVE, DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 ($ MILLIONS) 128 TABLE 83 MALARIAL PREVENTION PRODUCT MARKET IN ASIA BY REGION, THROUGH 2017 ($ MILLIONS) 129 TABLE 84 MALARIAL DIAGNOSTIC PRODUCT MARKET IN ASIA BY REGION,

Global Markets and Technologies for Pandemic Control (From Issuu)

Page 18/22


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! THROUGH 2017 ($ MILLIONS) 129 TABLE 85 MALARIAL PHARMACEUTICAL PRODUCT MARKET IN ASIA BY REGION, THROUGH 2017 ($ MILLIONS) 130 TABLE 86 PROCESS OF CREATING DRUG TREATMENTS IN THE U.S. 132 TABLE 87 PANDEMIC DISEASE PHARMACEUTICAL PRODUCT PIPELINE, 2012 141 TABLE 88 PANDEMIC PHARMACEUTICAL AND VACCINE PATENTS (FEBRUARY 2006-DECEMBER 2012) 150 TABLE 89 PANDEMIC DIAGNOSTIC PATENTS (MARCH 2005 THROUGH DECEMBER 2012) 154 TABLE 90 PANDEMIC PHARMACEUTICAL AND VACCINE PRODUCT PATENTS (JANUARY 2005 THROUGH DECEMBER 2012) 155 TABLE 91 PANDEMIC DIAGNOSTIC PRODUCT PATENTS (JANUARY 2005 THROUGH DECEMBER 2012) 156 TABLE 92 PANDEMIC PRODUCT DIAGNOSIS AND TREATMENT PATENTS, BY COUNTRY (JANUARY 2005 THROUGH DECEMBER 2012) 157 TABLE 93 PATENTS ISSUED FOR DIAGNOSIS AND TREATMENT OF PANDEMIC DISEASES (MARCH 2005 THROUGH OCTOBER 2012) 158 TABLE 94 ABBOTT PHARMACEUTICAL PRODUCTS 161 TABLE 95 ABBOTT DIAGNOSTIC PRODUCTS 161 TABLE 96 ALERE DIAGNOSTIC PRODUCTS 162 TABLE 97 ALFA SCIENTIFIC DESIGNS DIAGNOSTIC PRODUCTS 163 TABLE 98 ATLAS LINK BIOTECH DIAGNOSTIC PRODUCTS 163 TABLE 99 BAXTER PHARMACEUTICAL PRODUCTS 164 TABLE 100 BAYER PHARMACEUTICAL PRODUCTS 164 TABLE 101 BIO-RAD DIAGNOSTIC PRODUCTS 165 TABLE 102 BOEHRINGER INGELHEIM PHARMACEUTICAL PRODUCTS 165 TABLE 103 BRISTOL-MYERS SQUIBB PHARMACEUTICAL PRODUCTS 166 TABLE 104 CREATIVE DIAGNOSTICS DIAGNOSTIC PRODUCTS 167 TABLE 105 DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS DIAGNOSTIC PRODUCTS 167 TABLE 106 DIAGNOSTIC PRODUCTS 168 TABLE 107 PHARMACEUTICAL PRODUCTS 169 TABLE 108 ENZO BIOCHEM DIAGNOSTIC PRODUCTS 169 TABLE 109 DIAGNOSTIC PRODUCT 170 TABLE 110 GILEAD SCIENCES PHARMACEUTICAL PRODUCTS 171 TABLE 111 GSK PHARMACEUTICAL PRODUCTS 171 TABLE 112 HOME ACCESS HEALTH DIAGNOSTIC PRODUCTS 172 TABLE 113 IMMUNOSTICS DIAGNOSTIC PRODUCTS 173 TABLE 114 IND DIAGNOSTIC PRODUCTS 173 TABLE 115 JANSSEN THERAPEUTICS PHARMACEUTICAL PRODUCTS 174 TABLE 116 MERCK PHARMACEUTICAL PRODUCTS 175 TABLE 117 NOVARTIS DIAGNOSTIC PRODUCTS 176 TABLE 118 ORASURE DIAGNOSTIC PRODUCTS 176 TABLE 119 ORTHO DIAGNOSTIC PRODUCTS 177 TABLE 120 PFIZER PHARMACEUTICAL PRODUCTS 177 TABLE 121 PRINCETON BIOMEDITECH DIAGNOSTIC PRODUCTS 178 TABLE 122 ROCHE PHARMACEUTICAL PRODUCTS 179 TABLE 123 SANOFI PASTEUR PHARMACEUTICAL PRODUCTS 180

Global Markets and Technologies for Pandemic Control (From Issuu)

Page 19/22


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! TABLE 124 SCICLONE PHARMACEUTICALS PHARMACEUTICAL PRODUCTS 181 TABLE 125 SHANGHAI KEHUA BIO-ENGINEERING DIAGNOSTIC PRODUCTS 181 TABLE 126 STANDARD DIAGNOSTICS DIAGNOSTIC PRODUCTS 182 TABLE 127 TRINITY BIOTECH DIAGNOSTIC PRODUCTS 183 TABLE 128 VERTEX PHARMACEUTICALS PHARMACEUTICAL PRODUCTS 183 TABLE 129 VIIV HEALTHCARE PHARMACEUTICAL PRODUCTS 184

LIST OF FIGURES SUMMARY FIGURE PROJECTED MARKET FOR PANDEMIC INFECTIOUS DISEASE PRODUCTS, BY REGION, 2012 AND 2017 (%) 7 FIGURE 1 TOP PHARMACEUTICAL MANUFACTURERS IN THE HEPATITIS MARKET AND THEIR MARKET SHARE, 2011 (%) 36 FIGURE 2 MARKET SHARE FOR BRANDED HIV DRUGS BY MANUFACTURER, 2011 (%) 44 FIGURE 3 PROJECTED GLOBAL MARKET FOR DIAGNOSTIC PRODUCTS USED TO DETECT HIV AND HEPATITIS PANDEMIC DISEASES, 2012 AND 2017 (%) 81 FIGURE 4 GLOBAL MARKET FOR VIRAL PANDEMIC PHARMACEUTICAL PRODUCTS, 2012 AND 2017 (%) 83 FIGURE 5 MARKET SHARES FOR HEPATITIS C TREATMENTS, 2010 (%) 88 FIGURE 6 GLOBAL PANDEMIC VIRAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, 2012 AND 2017 (%) 89 FIGURE 7 GLOBAL PANDEMIC PHARMACEUTICAL MARKET, 2012 AND 2017 (%) 91 FIGURE 8 MARKET FOR PANDEMIC DIAGNOSTIC PRODUCTS IN ASIA 2012 AND 2017 (%) 96 FIGURE 9 DIAGNOSTIC AND PHARMACEUTICAL PATENTS ISSUED (BETWEEN MARCH 2005 AND DECEMBER 2012) (%) 158

Global Markets and Technologies for Pandemic Control (From Issuu)

Page 20/22


Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: ƒ ƒ

Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93

If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information Please verify that the product information is correct and select the format(s) you require. Global Markets and Technologies for Pandemic Control

Product Formats Please select the product formats and the quantity you require. 1 User License--USD 5 450.00

Quantity: _____

Department License--USD 6 650.00

Quantity: _____

Corporate License--USD 9 350.00

Quantity: _____

Contact Information Please enter all the information below in BLOCK CAPITALS

Title:

Mr

Mrs

Dr

Miss

Ms

Prof

First Name:

_____________________________ Last Name: __________________________________

Email Address:

__________________________________________________________________________

Job Title:

__________________________________________________________________________

Organization:

__________________________________________________________________________

Address:

__________________________________________________________________________

City:

__________________________________________________________________________

Postal / Zip Code:

__________________________________________________________________________

Country:

__________________________________________________________________________

Phone Number:

__________________________________________________________________________

Fax Number:

__________________________________________________________________________

Global Markets and Technologies for Pandemic Control (From Issuu)

Page 21/22


Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card

Card Number: ______________________________________________

Expiry Date

__________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer

Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check

UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms

Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56

ƒ ƒ

Asia, Oceania and America : + 1 (805) 617 17 93

Global Markets and Technologies for Pandemic Control (From Issuu)

Page 22/22

Global Markets and Technologies for Pandemic Control  

REPORT SCOPEINTRODUCTIONREASONS FOR DOING THE STUDYThe spread of human immunodeficiency virus (HIV), hepatitis B and C, evolving influenza s...